percent fluorine and having a Mooney Viscosity of at least 28, for use as a processing aid at a level not to exceed 0.2 percent by weight of ethylene-vinyl acetate copolymers.

* * * * *

Dated: April 24, 1990.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 90-10284 Filed 5-2-90; 8:45 am]

BILLING CODE 4160-01-M

21 CFR Part 177

[Docket No. 89F-0051]

Indirect Food Additives: Polymers

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the food additive regulations to provide for an increase in the permitted fluorine content of vinylidene fluoride-hexafluoropropene copolymers, for an increase in the weight-percent of vinylidene fluoride-hexafluoropropene copolymers used as adjuvants in the production of olefin polymers, and for the use of vinylidene fluoride-hexafluoropropene copolymers in olefin polymers in contact with alcoholic foods. This action responds to a petition filed by Minnesota Mining and Manufacturing Co.

DATES: Effective May 3, 1990; written objections and requests for a hearing by June 4, 1990.

ADDRESSES: Written objections to the Dockets Management Branch (HFA-305), Food and Drug Administration, Rm. 4-62, 5600 Fishers Lane, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Richard H. White, Center for Food Safety and Applied Nutrition (HFF-335), Food and Drug Administration, 200 C Street SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: In a notice published in the **Federal Register** of March 15, 1989 (54 FR 10727), FDA announced that a food additive petition (FAP 9B4129) had been filed by Minnesota Mining and Manufacturing Co., 3M Center, St. Paul, MN 55144-1000, proposing that § 177.1520 *Olefin polymers* (21 CFR 177.1520) be amended to provide for additional vinylidene fluoride-hexafluoropropene copolymers as adjuvants in the production of olefin polymers.

FDA has evaluated data in the petition and other relevant material. The agency concludes that the proposed food additive use is safe, and that § 177.1520 should be amended in the table in paragraph (b) by revising the entry for vinylidene fluoride-hexafluoropropene copolymer to increase the fluorine content of the polymers, to provide for a higher viscosity and use level, and to remove the restriction on use with alcoholic food as set forth below.

In accordance with § 171.1(h) (21 CFR 171.1(h)), the petition and the documents that FDA considered and relied upon in reaching its decision to approve the petition are available for inspection at the Center for Food Safety and Applied Nutrition by appointment with the information contact person listed above. As provided in 21 CFR 171.1(h), the agency will delete from the documents any materials that are not available for public disclosure before making the documents available for inspection.

The agency has carefully considered the potential environmental effects of this action. FDA has concluded that the action will not have a significant impact on the human environment, and that an environmental impact statement is not required. The agency's finding of no significant impact and the evidence supporting the finding, contained in an environmental assessment, may be seen in the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday.

Any person who will be adversely affected by this regulation may at any time on or before June 4, 1990 file with the Dockets Management Branch (address above) written objections thereto. Each objection shall be separately numbered, and each numbered objection shall specify with particularity the provisions of the regulation to which objection is made and the grounds for the objection. Each numbered objection on which a hearing is requested shall specifically so state. Failure to request a hearing for any particular objection shall constitute a waiver of the right to a hearing on that objection. Each numbered objection for which a hearing is requested shall include a detailed description and analysis of the specific factual information intended to be presented in support of the objection in the event that a hearing is held. Failure to include such a description and anlaysis for any particular objection shall constitute a waiver of the right to a hearing on the objection. Three copies of all documents shall be submitted and shall be identified with the docket number found in brackets in the heading of this document. Any objections received in response to the regulation may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

List of Subjects in 21 CFR Part 177

Food additives, Food packaging, Incorporation by reference.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Director of the Center for Food Safety and Applied Nutrition, 21 CFR part 177 is amended as follows:

PART 177—INDIRECT FOOD ADDITIVES: POLYMERS

1. The authority citation for 21 CFR part 177 continues to read as follows:

Authority: Secs. 201, 402, 409, 706 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321, 342, 348, 376).

2. Section 177.1520 is amended in the table in paragraph (b) by revising the entry for "Vinylidene fluoride-hexafluoropropene copolymer * * *" under the headings "Substance" and "Limitations" to read as follows:

§ 177.1520 Olefin polymers.

* * * * *

(b) * * *

Substance	Limitations
* * * * *	
Vinylidene flouride-hexafluoropropene copolymer (CAS Reg. No. 9011-17-0) having a fluorine content of 65 to 71 percent and a Mooney viscosity of a least 28, as determined by a method entitled "Mooney Viscosity," which is incorporated by reference in accordance with 5 U.S.C. 552(a). Copies are available from the Division of Food and Color Additives, Center for Food Safety and Applied Nutrition (HFF-330), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, or may be examined at the Office of the Federal Register, 1100 L St. NW., Washington, DC.	For use only as an extrusion aid in the production of extruded olefin polymers at levels not to exceed 0.2 percent by weight of the polymer. The finished polymers may be used only under the conditions described in § 176.170(c) of this chapter, Table 2, under conditions of use B through H.
* * * * *	

Dated: April 25, 1990.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 90-10288 Filed 5-2-90; 8:45 am]

BILLING CODE 4160-01-M

21 CFR Part 178

[Docket No. 88F-0382]

Indirect Food Additives: Adjuvants, Production Aids, and Sanitizers

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the food additive regulations to provide for the safe use of carbethoxymethyl diethyl phosphonate as a stabilizer in polyethylene terephthalate and related polyesters for food-contact use. This action is in response to a petition filed by Springborn Testing Institute, Inc., on behalf of Enka bv.

DATES: Effective May 3, 1990; written objections and requests for a hearing by June 4, 1990.

FOR FURTHER INFORMATION CONTACT: Marvin D. Mack, Center for Food Safety and Applied Nutrition (HFF-335), Food and Drug Administration, 200 C Street SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: In a notice published in the **Federal Register** of January 6, 1989 (54 FR 484), FDA announced that a food additive petition (FAP 8B4087) had been filed by Springborn Testing Institute, Inc., 20 Springborn Center, Enfield, CT 06082, on behalf of Enka bv of the Netherlands, proposing that § 178.2010 *Antioxidants and/or stabilizers for polymers* (21 CFR 178.2010) be amended to provide for the safe use of carbethoxymethyl-diethyl phosphonate as a stabilizer in polyethylene terephthalate and related polyesters for food-contact use.

FDA has evaluated data in the petition and other relevant material. The agency concludes that the proposed use of the additive in the manufacture of polyethylene-terephthalate and related polyesters is safe, and that the regulations should be amended in § 178.2010(b) in the table by alphabetically adding a new entry as set forth below.

In accordance with § 171.1(h) (21 CFR 171.1(h)), the petition and the documents that FDA considered and relied upon in reaching its decision to approve the petition are available for inspection at the Center for Food Safety and Applied Nutrition by appointment with the information contact person listed above. As provided in 21 CFR 171.1(h), the agency will delete from the documents any materials that are not available for public disclosure before making the documents available for inspection.

The agency has carefully considered the potential environmental effects of this action. FDA has concluded that the action will not have a significant impact on the human environment, and that an environmental impact statement is not required. The agency's finding of no significant impact and the evidence supporting that finding, contained in an environmental assessment, may be seen in the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday.

Any person who will be adversely affected by this regulation may at any time on or before June 4, 1990, file with the Dockets Management Branch (address above) written objections thereto. Each objection shall be separately numbered, and each numbered objection shall specify with particularity the provisions of the regulation to which objection is made and the grounds for the objection. Each numbered objection on which a hearing is requested shall specifically so state. Failure to request a hearing for any particular objection shall constitute a waiver of the right to a hearing on that objection. Each numbered objection for which a hearing is requested shall include a detailed description and analysis of the specific factual information intended to be presented in support of the objection in the event that a hearing is held. Failure to include such a description and analysis for any particular objection shall constitute a waiver of the right to a hearing on the objection. Three copies of all documents shall be submitted and shall be identified with the docket number found in brackets in the heading of this document. Any objections received in response to the regulation may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

List of Subjects in 21 CFR Part 178

Food additives, Food packaging.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Director, Center for Food Safety and Applied Nutrition, 21 CFR part 178 is amended as follows:

PART 178—INDIRECT FOOD ADDITIVES: ADJUVANTS, PRODUCTION AIDS, AND SANITIZERS

1. The authority citation for 21 CFR part 178 continues to read as follows:

Authority: Secs. 201, 402, 409, 706 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321, 342, 348, 376).

2. Section 178.2010 is amended in the table of paragraph (b) by alphabetically adding a new entry under the headings "Substances" and "Limitations" to read as follows:

§ 178.2010 Antioxidants and/or stabilizers for polymers.

* * * * *

(b) * * *

Substances	Limitations
* * * * *	
Carbethoxymethyl diethyl phosphonate (CAS Reg. No. 867-13-0).	At levels not to exceed 0.07 percent by weight of polyethylene phthalate polymers complying with § 177.1630 of this chapter.
* * * * *	

Dated: April 24, 1990.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 90-10289 Filed 5-2-90; 8:45 am]

BILLING CODE 4160-01-M

21 CFR Part 444

[Docket No. 89N-0380]

Antibiotic Drugs; Neomycin Sulfate-Polymyxin B Sulfate-Hydrocortisone Otic Suspension; pH Standard

AGENCY: Food and Frug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the antibiotic drug regulations for neomycin sulfate-polymyxin B sulfate-hydrocortisone otic suspension to extend the pH range for the product. This action is being taken to provide for a product that is less irritating to pediatric patients.

DATES: Effective June 4, 1990; written comments, notice of participation, and request for hearing by June 4, 1990; data, information, and analyses to justify a hearing by July 2, 1990.

ADDRESSES: Written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, Rm.

4–62, 5600 Fishers Lane, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Peter A. Dionne, Center for Drug Evaluation and Research (HFD–520, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–4290.

SUPPLEMENTARY INFORMATION: In the Federal Register of October 24, 1989 (54 FR 43303), FDA proposed to amend the antibiotic drug regulations for neomycin sulfate-polymyxin B sulfate-hydrocortisone otic suspension to extend the acceptable pH range for the product.

As discussed in the proposal, a manufacturer contended that a pH range of not less than 3.0 and not more than 5.5 for this product is inappropriate for pediatric patients because it may be irritating to the ear canal. In order to make the product less irritating for pediatric patients, the manufacturer submitted a petition requesting that a separate pH range of not less than 4.1 and not more than 7.0 be specified in the monograph for this product if it is intended for pediatric use.

FDA has determined that there is no need for separate pH standards for adult and pediatric use of this product, and amending the pH standard to extend the pH standard to not less than 3.0 and not more than 7.0 for this product would be sufficient to accomodate products with a higher pH.

Interested persons were given until December 26, 1989, to submit written comments on this proposal and until November 24, 1989, to submit requests for an informal conference. No comments or requests for an informal conference were received to the proposal. Therefore, FDA is amending 21 CFR 444.442g(a)(1) as set forth below.

Environmental Impact

The agency has determined under 21 CFR 25.24(c)(6) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

Economic Impact

The agency has considered the economic impact of this final rule and has determined that it does not require a Regulatory Flexibility Analysis, as defined in the Regulatory Flexibility Act (Pub. L. 96–354). Specifically, the final rule imposes a minor amendment to an existing requirement without imposing a more stringent requirement. Accordingly, the agency certifies that this rulemaking will not have a significant economic impact on a substantial number of small entities.

Submitting Comments and Filing Objections

Any person who will be adversely affected by this final rule may file objections to it and request a hearing. Reasonable grounds for the hearing must be shown. Any person who decides to seek a hearing must file: (1) On or before June 4, 1990, a written notice of participation and request for hearing; and (2) on or before July 2, 1990, the data, information, and analyses on which the person relies to justify a hearing, as specified in 21 CFR 314.300. A request for a hearing may not rest upon mere allegations or denials, but must set forth specific facts showing that there is a genuine and substantial issue of fact that requires a hearing. If it conclusively appears from the face of the data, information, and factual analyses in the request for hearing that no genuine and substantial issue of fact precludes the action taken by this order, or if a request for hearing is not made in the required format or with the required analyses, the Commissioner of Food and Drugs will enter summary judgment against the person(s) who request(s) the hearing, making findings and conclusions and denying a hearing. All submissions must be filed in three copies, identified with the docket number appearing in the heading of this document and filed with the Dockets Management Branch (address above).

The procedures and requirements governing this order, a notice of participation and request for hearing, a submission of data, information, and analyses to justify a hearing, other comments, and grant or denial of a hearing are contained in 21 CFR 314.300.

All submissions under this order, except for data and information prohibited from public disclosure under 21 U.S.C. 331(j) or 18 U.S.C. 1905, may be seen in the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday.

List of Subjects in 21 CFR Part 444

Antibiotics.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR part 444 is amended as follows:

PART 444—OLIGOSACCHARIDE ANTIBIOTIC DRUGS

1. The authority citation for 21 CFR part 444 continues to read as follows:

Authority: Sec. 507 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 357).

2. Section 444.442g is amended by revising the sixth sentence in paragraph (a)(1) to read as follows:

§ 444.442g Neomycin sulfate-polymyxin B sulfate-hydrocortisone otic suspension.

(a) * * *

(1) * * * Its pH is not less than 3.0 and not more than 7.0 * * *

* * * * *

Dated: April 19, 1990.

Sammie R. Young,

Deputy Director, Office of Compliance Center for Drug Evaluation and Research.

[FR Doc. 90–10286 Filed 5–2–90; 8:45 am]

BILLING CODE 4160–01–M

---

21 CFR Part 558

New Animal Drugs for Use in Animal Feeds; Pyrantel Tartrate

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect the approval of a new animal drug application (NADA) filed by Pfizer, Inc. The NADA provides for the use of a 48-gram-per-pound pyrantel tartrate Type A medicated article in manufacturing a Type B medicated feed for addition to the daily grain ration of horses as an anthelmintic. The regulations are amended in the Category II table of 21 CFR 558.4 by increasing the maximum level of pyrantel tartrate permitted in a Type B medicated feed.

EFFECTIVE DATE: May 3, 1990.

FOR FURTHER INFORMATION CONTACT: Sandra K. Woods, Center for Veterinary Medicine (HFV–114), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–3420.

SUPPLEMENTARY INFORMATION: Pfizer, Inc., 235 East 42d St., New York, NY 10017, filed NADA 140–819. The NADA provides for the use of a Type A medicated article containing 48 grams of pyrantel tartrate per pound in manufacturing a Type B medicated feed (pellets). The pyrantel tartrate pellets are subsequently administered to horses by either top-dressing or mixing them into the animals' daily grain ration. The resulting medicated feed is indicated for the prevention of *Strongylus vulgaris* larval infections and for the control of certain strongyle, pinworm, and ascarid infections.

The NADA is approved and 21 CFR 558.485 is amended by revising

paragraphs (a)(1) through (a)(23), (a)(25), and (a)(27); by removing from the introductory text of paragraph (e) the phrase "in feed for swine"; by redesignating paragraphs (e)(1) through (e)(12) as set forth in the table below; by adding new paragraphs (e)(1) and (e)(2); and by revising newly redesignated paragraphs (e)(1)(x)(B) and (e)(1)(xi)(B) to reflect the approval. The basis for the approval is discussed in the freedom of information summary.

This approval provides for administering pyrantel tartrate to a new species (horses) at a maximum continuous feed use level of 12,000 grams per ton or 6 grams per pound (1.323 percent) as a top-dress on their daily grain ration. This use level necessitates increasing the maximum concentration of pyrantel tartrate permitted in a Type B medicated feed (based on swine use) as specified in the Category II table of 21 CFR 558.4. The increase is necessary because of the definition of a Type B medicated feed in 21 CFR 558.3(b), which provides that such a feed's maximum drug concentration may be no greater than 100 times the highest continuous use level and that it must contain at least 25 percent by weight nutritional ingredients. Hence, to produce the Type B feed, the Type A medicated article, which is nearly all pyrantel tartrate, must have its drug concentration reduced to 75 percent of 48 grams per pound, or 36 grams per pound. Accordingly, the regulations are further amended to increase the maximum concentration of pyrantel tartrate permitted in Type B feeds from 4.8 grams per pound to 36 grams per pound in the Category II table of § 558.4.

Additionally, because a Category II, Type A medicated article is involved, medicated feed applications (Form FDA 1900's) are required when the article is used to manufacture Type B medicated feeds. (The article is not approved for use in the manufacture of Type C medicated feed.)

REDESIGNATION TABLE

Old section	New section
558.485(e)(1)	558.485(e)(1)(i)
558.485(e)(1)(i)	558.485(e)(1)(i)(A)
558.485(e)(1)(ii)	558.485(e)(1)(i)(B)
558.485(e)(2)	558.485(e)(1)(ii)
558.485(e)(2)(i)	558.485(e)(1)(ii)(A)
558.485(e)(2)(ii)	558.485(e)(1)(ii)(B)
558.485(e)(3)	558.485(e)(1)(iii)
558.485(e)(3)(i)	558.485(e)(1)(iii)(A)
558.485(e)(3)(ii)	558.485(e)(1)(iii)(B)
558.485(e)(4)	558.485(e)(1)(iv)
558.485(e)(4)(i)	558.485(e)(1)(iv)(A)
558.485(e)(4)(ii)	558.485(e)(1)(iv)(B)
558.485(e)(5)	558.485(e)(1)(v)
558.485(e)(5)(i)	558.485(e)(1)(v)(A)
558.485(e)(5)(ii)	558.485(e)(1)(v)(B)
558.485(e)(6)	558.485(e)(1)(vi)
558.485(e)(6)(i)	558.485(e)(1)(vi)(A)
558.485(e)(6)(ii)	558.485(e)(1)(vi)(B)
558.485(e)(7)	558.485(e)(1)(vii)
558.485(e)(7)(i)	558.485(e)(1)(vii)(A)
558.485(e)(7)(ii)	558.485(e)(1)(vii)(B)
558.485(e)(8)	558.485(e)(1)(viii)
558.485(e)(8)(i)	558.485(e)(1)(viii)(A)
558.485(e)(8)(ii)	558.485(e)(1)(viii)(B)
558.485(e)(9)	558.485(e)(1)(ix)
558.485(e)(9)(i)	558.485(e)(1)(ix)(A)
558.485(e)(9)(ii)	558.485(e)(1)(ix)(B)
558.485(e)(10)	558.485(e)(1)(x)
558.485(e)(10)(i)	558.485(e)(1)(x)(A)
558.485(e)(10)(ii)	558.485(e)(1)(x)(B)
558.485(e)(11)	558.485(e)(1)(xi)
558.485(e)(11)(i)	558.485(e)(1)(xi)(A)
558.485(e)(11)(ii)	558.485(e)(1)(xi)(B)
558.485(e)(12)	558.485(e)(1)(xii)
558.485(e)(12)(i)	558.485(e)(1)(xii)(A)
558.485(e)(12)(ii)	558.485(e)(1)(xii)(B)
558.485(e)(12)(iii)	558.485(e)(1)(xii)(C)

REDESIGNATION TABLE—Continued

Old section	New section
558.485(e)(5)(ii)	558.485(e)(1)(v)(B)
558.485(e)(6)	558.485(e)(1)(vi)
558.485(e)(6)(i)	558.485(e)(1)(vi)(A)
558.485(e)(6)(ii)	558.485(e)(1)(vi)(B)
558.485(e)(7)	558.485(e)(1)(vii)
558.485(e)(7)(i)	558.485(e)(1)(vii)(A)
558.485(e)(7)(ii)	558.485(e)(1)(vii)(B)
558.485(e)(8)	558.485(e)(1)(viii)
558.485(e)(8)(i)	558.485(e)(1)(viii)(A)
558.485(e)(8)(ii)	558.485(e)(1)(viii)(B)
558.485(e)(9)	558.485(e)(1)(ix)
558.485(e)(9)(i)	558.485(e)(1)(ix)(A)
558.485(e)(9)(ii)	558.485(e)(1)(ix)(B)
558.485(e)(10)	558.485(e)(1)(x)
558.485(e)(10)(i)	558.485(e)(1)(x)(A)
558.485(e)(10)(ii)	558.485(e)(1)(x)(B)
558.485(e)(11)	558.485(e)(1)(xi)
558.485(e)(11)(i)	558.485(e)(1)(xi)(A)
558.485(e)(11)(ii)	558.485(e)(1)(xi)(B)
558.485(e)(12)	558.485(e)(1)(xii)
558.485(e)(12)(i)	558.485(e)(1)(xii)(A)
558.485(e)(12)(ii)	558.485(e)(1)(xii)(B)
558.485(e)(12)(iii)	558.485(e)(1)(xii)(C)

In accordance with the freedom of information provisions of part 20 (21 CFR part 20) and § 514.11(e)(2)(ii) (21 CFR 514.11(e)(2)(ii)), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA–305), Food and Drug Administration, Rm. 4–62, 5600 Fishers Lane, Rockville, MD 20857, from 9 a.m. to 4 p.m., Monday through Friday.

This approval qualifies for 3 years of marketing exclusivity beginning April 18, 1990, because the criteria for such exclusivity under the Generic Animal Drug and Patent Term Restoration Act of 1988 and section 512(c)(2)(F)(ii) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(ii)) have been met.

The agency has carefully considered the potential environmental effects of this action. FDA has concluded that the action will not have a significant impact on the human environment, and that an environmental impact statement is not required. The agency's finding of no significant impact and the evidence supporting that finding, contained in an environmental assessment, may be seen in the Dockets Management Branch (address above), between 9 a.m. and 4 p.m., Monday through Friday.

List of Subjects in 21 CFR Part 558

Animal drugs, Animal feeds.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 558 is amended as follows:

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

1. The authority citation for 21 CFR part 558 continues to read as follows:

Authority: Sec. 512, 701 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b, 371).

§ 558.4 [Amended]

2. Section 558.4 *Medicated feed applications* is amended in paragraph (d), in the Category II table, at the entry for "Pyrantel tartrate", under the heading "Type B maximum (100x)" by removing "4.8 g/1b (1.1%)" and replacing it with "36 g/1b (7.9%)".

3. Section 558.485 is amended by revising paragraphs (a)(1) through (a)(23), (a)(25), and (a)(27); by removing from the introductory text of paragraph (e) the phrase "in feed for swine"; by redesignating paragraphs (e)(1) through (e)(12) as set forth in the table below; by adding new paragraph (e)(1), introductory text and new paragraph (e)(2); and by revising newly redesignated paragraphs (e)(1)(x)(B) and (e)(1)(xi)(B) to read as follows:

REDESIGNATION TABLE

Old section	New section
558.485(e)(1)	558.485(e)(1)(i)
558.485(e)(1)(i)	558.485(e)(1)(i)(A)
558.485(e)(1)(ii)	558.485(e)(1)(i)(B)
558.485(e)(2)	558.485(e)(1)(ii)
558.485(e)(2)(i)	558.485(e)(1)(ii)(A)
558.485(e)(2)(ii)	558.485(e)(1)(ii)(B)
558.485(e)(3)	558.485(e)(1)(iii)
558.485(e)(3)(i)	558.485(e)(1)(iii)(A)
558.485(e)(3)(ii)	558.485(e)(1)(iii)(B)
558.485(e)(4)	558.485(e)(1)(iv)
558.485(e)(4)(i)	558.485(e)(1)(iv)(A)
558.485(e)(4)(ii)	558.485(e)(1)(iv)(B)
558.485(e)(5)	558.485(e)(1)(v)
558.485(e)(5)(i)	558.485(e)(1)(v)(A)
558.485(e)(5)(ii)	558.485(e)(1)(v)(B)
558.485(e)(6)	558.485(e)(1)(vi)
558.485(e)(6)(i)	558.485(e)(1)(vi)(A)
558.485(e)(6)(ii)	558.485(e)(1)(vi)(B)
558.485(e)(7)	558.485(e)(1)(vii)
558.485(e)(7)(i)	558.485(e)(1)(vii)(A)
558.485(e)(7)(ii)	558.485(e)(1)(vii)(B)
558.485(e)(8)	558.485(e)(1)(viii)
558.485(e)(8)(i)	558.485(e)(1)(viii)(A)
558.485(e)(8)(ii)	558.485(e)(1)(viii)(B)
558.485(e)(9)	558.485(e)(1)(ix)
558.485(e)(9)(i)	558.485(e)(1)(ix)(A)
558.485(e)(9)(ii)	558.485(e)(1)(ix)(B)
558.485(e)(10)	558.485(e)(1)(x)
558.485(e)(10)(i)	558.485(e)(1)(x)(A)
558.485(e)(10)(ii)	558.485(e)(1)(x)(B)
558.485(e)(11)	558.485(e)(1)(xi)
558.485(e)(11)(i)	558.485(e)(1)(xi)(A)
558.485(e)(11)(ii)	558.485(e)(1)(xi)(B)
558.485(e)(12)	558.485(e)(1)(xii)
558.485(e)(12)(i)	558.485(e)(1)(xii)(A)
558.485(e)(12)(ii)	558.485(e)(1)(xii)(B)
558.485(e)(12)(iii)	558.485(e)(1)(xii)(C)

§ 558.485 Pyrantel tartrate.

(a) * * *

(1) To 000069: 9.6, 19.2, 48 and 80 grams per pound, paragraph (e)(1) of this section; 48 grams per pound, paragraph (e)(2) of this section.

(2) To 017800: 19.2 and 48 grams per pound, paragraphs (e)(1)(i) through (e)(1)(iii) of this section.

(3) To 016968: 9.6 and 19.2 grams per pound, paragraphs (e)(1)(i) through (e)(1)(iii) of this section.

(4) To 026186: 9.6 and 19.2 grams per pound, paragraphs (e)(1)(i) through (e)(1)(iii) of this section.

(5) To 017790: 9.6 and 19.2 grams per pound, paragraphs (e)(1)(i) through (e)(1)(iii) of this section.

(6) To 018083: 9.6 and 19.2 grams per pound, paragraphs (e)(1)(i) through (e)(1)(iii) of this section.

(7) To 051359: 9.6 and 19.2 grams per pound, paragraphs (e)(1)(i) through (e)(1)(iii) of this section.

(8) To 011490: 9.6 and 19.2 grams per pound, paragraphs (e)(1)(i) through (e)(1)(iii) of this section.

(9) To 011749: 9.6 and 19.2 grams per pound, paragraphs (e)(1)(i) through (e)(1)(iii) of this section.

(10) To 043733: 9.6 and 19.2 grams per pound, paragraphs (e)(1)(i) through (e)(1)(iii) of this section.

(11) To 017274: 9.6 and 19.2 grams per pound, paragraphs (e)(1)(i) through (e)(1)(iii) of this section.

(12) To 046987: 9.6 and 19.2 grams per pound, paragraphs (e)(1)(i) and (e)(1)(ii) of this section.

(13) To 034936: 9.6 and 19.2 grams per pound, paragraphs (e)(1)(i) and (e)(1)(ii) of this section.

(14) To 021810: 9.6 grams per pound, paragraphs (e)(1)(i) through (e)(1)(iii) of this section.

(15) To 049685: 9.6 and 19.2 grams per pound, paragraphs (e)(1)(i) through (e)(1)(iii) of this section.

(16) To 012190: 9.6 and 19.2 grams per pound, paragraphs (e)(1)(i) through (e)(1)(iii) of this section.

(17) To 047427: 9.6 and 19.2 grams per pound, paragraphs (e)(1)(i) and (e)(1)(ii) of this section.

(18) To 001800: 9.6 grams per pound, paragraphs (e)(1)(i) through (e)(1)(iii) of this section.

(19) To 050568: 9.6 and 19.2 grams per pound, paragraphs (e)(1)(i) through (e)(1)(iii) of this section.

(20) To 050639: 9.6 and 19.2 grams per pound, paragraphs (e)(1)(i) through (e)(1)(iii) of this section.

(21) To 043734: 9.6 and 19.2 grams per pound, paragraphs (e)(1)(i) through (e)(1)(iii) of this section.

(22) To 017473: 9.6 and 19.2 grams per pound, paragraphs (e)(1)(i) through (e)(1)(iii) of this section.

(23) To 021676: 19.2 grams per pound, paragraphs (e)(1)(i) through (e)(1)(iii) of this section.

* * * * *

(25) To 020275: 9.6 and 19.2 grams per pound, paragraphs (e)(1)(i) through (e)(1)(iii) of this section.

* * * * *

(27) To 010439: 9.6 and 19.2 grams per pound, paragraphs (e)(1)(i) through (e)(1)(iii) of this section.

* * * * *

(e) * * *

(1) *Swine*—(i) * * *

* * * * *

(x) * * *

(B) *Limitations.* Administer in accordance with paragraph (c)(2)(i), (c)(2)(ii), or (c)(2)(iii) of § 558.325 and paragraph (e)(1)(ii)(B) of this section.

(xi) * * *

(B) *Limitations.* Administer in accordance with paragraph (c)(2)(i), (c)(2)(ii), or (c)(2)(iii) of § 558.325 and paragraph (e)(1)(iii)(B) of this section.

* * * * *

(2) *Horses*—(i) *Amount.* 1.2 milligrams per pound (2.64 milligrams per kilogram) of body weight.

(A) *Indications for use.* Prevention of *Strongylus vulgaris* larval infections; control of adult large strongyles (*S. vulgaris, S. edentatus,* and *Triodontophorus* spp.), adult and 4th stage larvae small strongyles (*Cyathostomum* spp., *Cylicocyclus* spp., *Cylicostephanus* spp., *Cylicodontophorus* spp., *Poteriostomum* spp.), adult and 4th stage larvae pinworms (*Oxyuris equi*), and adult and 4th stage larvae ascarids (*Parascaris equorum).*

(B) *Limitations.* Administer either as a top-dress (not to exceed 12,000 grams per ton) or mixed in the horse's daily grain ration (not to exceed 1,200 grams per ton) during the time that the animal is at risk of exposure to internal parasites. Not for use in horses intended for food. Consult your veterinarian before using in severly debilitated animals and for assistance in the diagnosis, treatment, and control of parasitism.

Dated: April 17, 1990.

Gerald B. Guest,

Director, Center for Veterinary Medicine.

[FR Doc. 90-10285 Filed 5-2-90; 8:45 am]

BILLING CODE 4160-01-M

DEPARTMENT OF DEFENSE

Department of the Air Force

32 CFR 847

Authentication of Official Air Force Records for Admission Into Evidence

AGENCY: Department of the Air Force, Department of Defense.

ACTION: Final rule.

SUMMARY: The Department of the Air Force is amending title 32, chapter VII of the CFR by removing part 847, Authentication of Official Records For Admission Into Evidence. This rule is removed because it has limited applicability to the general public. This action is the result of departmental review. The intended effect is to insure that only regulations which substantially affect the public are maintained in the Air Force portion of the Code of Federal Regulations.

EFFECTIVE DATE: June 4, 1990.

FOR FURTHER INFORMATION CONTACT: Ms. Patsy J. Conner, Air Force Federal Register Liaison Officer, SAF/AAIA, Pentagon, Washington, DC 20330-1000, telephone (202-694-3431).

SUPPLEMENTARY INFORMATION: Accordingly, 32 CFR, chapter VII, is amended by removing part 847.

Authority: 10 U.S.C. 8013.

PART 847—[REMOVED]

Patsy J. Conner,

Air Force Federal Register Liaison Officer.

[FR Doc. 90-10216 Filed 5-2-90; 8:45 am]

BILLING CODE 3910-01-M

DEPARTMENT OF TRANSPORTATION

Coast Guard

33 CFR Part 100

[CGD7 90-34]

Special Local Regulations; City of Fort Lauderdale

AGENCY: Coast Guard, DOT.

ACTION: Final rule.

SUMMARY: Special Local Regulations are being adopted for the City of Fort Lauderdale Whitbread Round the World Race. The event will be held on May 5, 1990, from approximately 12 a.m. edt to 2 p.m. edt. The regulations are needed to promote the safety of life on navigable waters during the event.

EFFECTIVE DATE: These regulations will become effective on May 5, 1990, at 9